Press release - 25/11/2021 New Collaborative Research Centre at Ulm University Focusing on the factors that influence human aging After a highly competitive process Ulm University has been awarded its fifth Collaborative Research Centre (CRC). The new CRC 1506 ‘Aging at Interfaces’ addresses one of the most urgent medical challenges of our time: the aging of the human body and the diseases and constraints that are frequently associated with the aging process.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-collaborative-research-centre-ulm-university-focusing-factors-influence-human-aging
Press release - 23/11/2021 Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
Press release - 18/11/2021 Overcoming resistance to cancer treatment: bone and soft tissue tumors in adolescents as a model system Treatment resistance is a central problem in the treatment of cancer. Bone and soft tissue tumors – known as sarcomas – in adolescents and young adults often stop responding to treatment too. This is because cancer cells develop a large number of new characteristics as the disease progresses and often become resistant to drugs that were originally effective.https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-cancer-treatment-bone-and-soft-tissue-tumors-adolescents-model-system
Press release - 15/11/2021 Using T cell to target malignant brain tumors Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-t-cell-target-malignant-brain-tumors
Press release - 04/11/2021 New Sensor Detects Ever Smaller Nanoparticles Nanoparticles are omnipresent in our environment: Viruses in ambient air, proteins in the body, as building blocks of new materials for electronics, or in surface coatings. Visualizing these smallest particles is a problem: They are so small that they can hardly be seen under an optical microscope.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-sensor-detects-ever-smaller-nanoparticles
Press release - 25/10/2021 How the "thermostat" in the brain measures impending overheating The mechanisms by which the body measures temperature and regulates its own body heat are vital, but still poorly understood. The discovery of the first heat sensor on nerve cells in the skin, for which the U.S. molecular biologist David Julius received this year's Nobel Prize for Medicine, was therefore pioneering.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-thermostat-brain-measures-impending-overheating
Optimised peptides against infections and cancer - 07/10/2021 New bioactive ingredients from the peptidome treasure chest Peptides are increasingly coming into scientific focus for application in diagnostics and therapy. The human body is full of these protein fragments, but only a fraction have been characterised. So there is enormous potential for discovering new biologically active substances that can help in the fight against bacteria, viruses and cancer. A collaborative research centre at Ulm University Hospital is on the trail of these promising fragments.https://www.gesundheitsindustrie-bw.de/en/article/news/new-bioactive-ingredients-peptidome-treasure-chest
Press release - 21/09/2021 Antibiotic levels measurable in breath for first time A team of engineers and biotechnologists at the University of Freiburg has for the first time shown in mammals that the concentration of antibiotics in the body can be determined using breath samples. The breath measurements also corresponded to the antibiotic concentrations in the blood. The team’s biosensor – a multiplex chip – will in future enable personalized dosing of medicines against infectious diseases on-site.https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibiotic-levels-measurable-breath-first-time
Press release - 09/09/2021 Machine learning improves biological image analysis Scientists use super-resolution microscopy to study previously undiscovered cellular worlds, revealing nanometer-scale details inside cells. This method revolutionized light microscopy and earned its inventors the 2014 Nobel Prize in Chemistry. In an international collaboration, AI researchers from Tübingen have now developed an algorithm that significantly accelerates this technology. https://www.gesundheitsindustrie-bw.de/en/article/press-release/machine-learning-improves-biological-image-analysis
Press release - 02/09/2021 Blood vessels produce growth factor that promotes metastases On the one hand, blood vessels supply tumors with nutrients and, on the other, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a distant organ is promoted by factors whose production is induced by the primary tumor itself. Scientists have now identified a new growth factor produced by blood vessels that enables tumor cells to metastatically colonize organs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-vessels-produce-growth-factor-promotes-metastases
Press release - 30/08/2021 CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the publication entitled “Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model” in the peer-reviewed Journal of Hepatology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-preclinical-data-demonstrates-significant-reduction-liver-fibrosis-mrna-therapeutic
Press release - 20/08/2021 Innovative Drug Discovery New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation. https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-drug-discovery
Press release - 16/08/2021 Blood-based micro-RNAs indicate the risk of colorectal cancer The risk of colorectal cancer can be predicted more accurately by determining seven blood-based micro-RNAs (miRNAs) than by using traditional methods - and can be done so many years before a diagnosis is made. In a current study, researchers from the German Cancer Research Center and the National Center for Tumor Diseases (NCT) Heidelberg show that miRNA profiles provide greater predictive accuracy than genetic or lifestyle-based risk…https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-based-micro-rnas-indicate-risk-colorectal-cancer
Press release - 26/07/2021 Vaccination against hereditary colorectal cancer successful in mice Scientists from the German Cancer Research Center and Heidelberg University Hospital have for the first time been able to delay the development of hereditary colorectal cancer with a protective vaccination. Mice with a hereditary predisposition to colorectal cancer survived significantly longer after vaccination than unvaccinated animals. Combining the vaccination with an anti-inflammatory drug increased the protective effect.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccination-against-hereditary-colorectal-cancer-successful-mice
Gene regulation - 20/07/2021 The many faces of the epigenetic regulator MOF Epigenetic modifications play a crucial role in coordinated gene transcription, and are required for a fertilised egg cell to be able to develop into an organism with different cell types. Dr. Asifa Akhtar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has been studying the essential epigenetic regulator protein MOF for 20 years.https://www.gesundheitsindustrie-bw.de/en/article/news/die-vielen-gesichter-des-epigenetischen-regulators-mof
Press release - 13/07/2021 Breakthrough in research on age-related macular degenerationtion Age-related macular degeneration (AMD) is the commonest cause of blindness in developed countries affecting seven million in total in Germany, from which 500,000 people are suffering from late stage disease, around half of whom are registered as visually impaired. There are two forms of AMD, ‘wet’ and ‘dry’. There are currently no treatments available for the dry form of the disease (geographic atrophy).https://www.gesundheitsindustrie-bw.de/en/article/press-release/breakthrough-research-age-related-macular-degenerationtion
Press release - 12/07/2021 Hijacked immune activator promotes growth and spread of colorectal cancer Through a complex, self-reinforcing feedback mechanism, colorectal cancer cells make room for their own expansion by driving surrounding healthy intestinal cells to death - while simultaneously fueling their own growth. This feedback loop is driven by an activator of the innate immune system. Researchers from the German Cancer Research Center (DKFZ) and the University of Heidelberg discovered this mechanism in the intestinal tissue of fruit…https://www.gesundheitsindustrie-bw.de/en/article/press-release/hijacked-immune-activator-promotes-growth-and-spread-colorectal-cancer
Article - 08/07/2021 Individual operation risk assessment by the Cognitive Medical Assistant Despite modern surgical techniques and anaesthetic procedures, serious complications can occur during surgical interventions. An interdisciplinary team at Heidelberg University Hospital has launched a project called the Cognitive Medical Assistant (German: Der Kognitive Medizinische Assistant, KoMed for short), designed to better assess the individual risk of these interventions. The project’s goal is to systematically and comprehensively analyse…https://www.gesundheitsindustrie-bw.de/en/article/news/individual-operation-risk-assessment-cognitive-medical-assistant
Press release - 25/05/2021 How “paralyzed” immune cells can be reactivated against brain tumors Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-paralyzed-immune-cells-can-be-reactivated-against-brain-tumors
Vaccine development - 25/05/2021 Vaccines - a beacon of hope in the fight against pandemics https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
Press release - 17/05/2021 New findings in genome research The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-genome-research
Press release - 14/04/2021 Engineering T cells for cancer therapy efficiently and safely Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/engineering-t-cells-cancer-therapy-efficiently-and-safely
Press release - 24/03/2021 Vaccination against mutated protein tested in brain tumor patients for the first time Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccination-against-mutated-protein-tested-brain-tumor-patients-first-time
Press release - 15/03/2021 How novel pathogens may cause the development of colorectal cancer Do BMMFs, the novel infectious agents found in dairy products and bovine sera, play a role in the development of colorectal cancer? Scientists led by Harald zur Hausen detected the pathogens in colorectal cancer patients in close proximity to tumors. The researchers show that the BMMFs trigger local chronic inflammation, which can cause mutations via activated oxygen molecules and thus promote cancer development in the long term.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-novel-pathogens-may-cause-development-colorectal-cancer
Press release - 04/03/2021 CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Novartis AG announced today that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-novartis-sign-initial-agreement-manufacturing-covid-19-vaccine-candidate-cvncov
Press release - 04/03/2021 Induced pluripotent stem cells reveal causes of disease Induced pluripotent stem cells (iPSC) are suitable for discovering the genes that underly complex and also rare genetic diseases. Scientists from the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL), together with international partners, have studied genotype-phenotype relationships in iPSCs using data from approximately one thousand donors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/induced-pluripotent-stem-cells-reveal-causes-disease
Press release - 24/02/2021 Supposedly "silent" mutation with serious consequences So-called silent mutations have no effect on the composition of a protein. They are therefore not considered to promote cancer. However, scientists from the German Consortium for Translational Cancer Research (DKTK), partner site Essen, now describe in a case of kidney cancer an overlooked silent mutation with a major impact on prognosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/supposedly-silent-mutation-serious-consequences
Press release - 24/02/2021 Disease progression in childhood cancer: Lengthening of telomeres promotes relapse Neuroblastoma can spread relentlessly or shrink spontaneously. Scientists from the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg and the National Center for Tumor Diseases (NCT) Heidelberg have shown that some malignant neuroblastomas employ a trick to avoid cell death: they use a special mechanism to lengthen the telomeres at the end of their chromosomes. https://www.gesundheitsindustrie-bw.de/en/article/press-release/disease-progression-childhood-cancer-lengthening-telomeres-promotes-relapse
Press release - 17/02/2021 A new piece of the HIV infection puzzle explored Researchers from EMBL and Heidelberg University Hospital combine high-resolution imaging to observe the infection process in cell nuclei, opening the door for new therapeutics.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-piece-hiv-infection-puzzle-explored
Press release - 01/02/2021 Targeting a rapid market breakthrough for new vaccine production method In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product. https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
Press release - 25/01/2021 Protein anchors as a newly discovered key molecule in cancer spread and epilepsy Certain anchor proteins inhibit a key metabolic driver that plays an important role in cancer and developmental brain disorders. Scientists from the German Cancer Research Center (DKFZ) and the University of Innsbruck, together with a Europe-wide research network, discovered this molecular mechanism, which could open up new opportunities for personalized therapies for cancer and neuronal diseases. They published their results in the journal Cell.https://www.gesundheitsindustrie-bw.de/en/article/press-release/protein-anchors-newly-discovered-key-molecule-cancer-spread-and-epilepsy
Press release - 18/01/2021 How a protein variant could explain resistance to sleeping sickness drug A specific variant of the surface protein VSG of African trypanosomes, the causative agents of sleeping sickness, is associated with resistance to the important drug Suramin. Scientists at the German Cancer Research Center have now been able to find a possible explanation for the formation of resistance based on the crystal structure of this protein variant.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-protein-variant-could-explain-resistance-sleeping-sickness-drug
Article - 14/01/2021 Newly discovered RNA as growth driver in liver cancer Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.https://www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
Press release - 11/01/2021 CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-non-human-primates-during-sars-cov-2-challenge-infe
Inside the fight against COVID-19 - 28/10/2020 A new immunotherapeutic agent for treating severe COVID-19 cases Apogenix, a Heidelberg-based biopharmaceutical company specialising in innovative immunotherapeutics, has initiated a Phase II clinical trial with asunercept, the company’s lead drug candidate for treating severe cases of COVID-19. The fusion protein blocks the CD95-ligand-mediated death of epithelial cells in the lung and thus prevents damage to the organ.https://www.gesundheitsindustrie-bw.de/en/article/news/new-immunotherapeutic-agent-treating-severe-covid-19-cases
Atriva Therapeutics - 21/10/2020 COVID-19 pioneer drug in Phase II clinical trial - with double the power The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…https://www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
KyooBe Tech GmbH - 08/10/2020 Next generation vaccine production For decades, conventional inactivated vaccines have been produced by killing pathogens with toxic chemicals. However, this process often changes the surface structure of the pathogens to such an extent that the immune system is only able to induce a weak response. KyooBe Tech GmbH is offering a method that uses low-energy electrons to inactivate pathogens. Vaccines produced this way are much higher quality, making them safer and more effective.https://www.gesundheitsindustrie-bw.de/en/article/news/next-generation-vaccine-production
Mosses for pharmaceutical production - 16/09/2020 Factor H as a therapeutic option for viral diseases - including COVID-19 The search for drug candidates for COVID-19 diseases is well underway. Factor H, which is part of the innate immune system, might also be a future therapeutic option. The Freiburg-based biotech company eleva has developed a technology for producing this human protein in moss cells. The active ingredient, which might also have a regulatory effect in other diseases, is currently undergoing preclinical testing.https://www.gesundheitsindustrie-bw.de/en/article/news/factor-h-therapeutic-option-viral-diseases-including-covid-19
Phytopharmaceuticals - 14/09/2020 Medicinal cannabis to be grown in Germany Anyone who thinks hemp is just an inconspicuous plant, whose ingredients can be used, at best, as an intoxicant, can quickly be proven wrong. Besides being used as a valuable raw material for textiles and building materials, the plant has great potential as a medicinal drug. The CANNABIS-NET network, coordinated by the University of Hohenheim, has been set up to establish the basis for producing medicinal hemp in Germany.https://www.gesundheitsindustrie-bw.de/en/article/news/medicinal-cannabis-be-grown-germany
Trenzyme GmbH - 20/05/2020 The SARS-CoV spike protein and its receptor The SARS-CoV-2 coronavirus uses a spike protein to bind to the ACE2 receptor on the cell surfaces of lung tissue. Additional cofactors are needed to allow the virus genome to penetrate human cells and multiply. Knowing these relationships can help understand the course of the infection and develop counterstrategies. To this end, the Constance-based company Trenzyme has produced a recombinant spike protein to support coronavirus research.https://www.gesundheitsindustrie-bw.de/en/article/news/the-sars-cov-spike-protein-and-its-receptor
Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB - 24/04/2020 A rapid pyrogen test: the human immune system as model Every year, around 11 million people die of sepsis (blood poisoning) caused by microorganisms or microbial residues, known as pyrogens, entering the bloodstream. The smallest amounts can trigger fever. Researchers from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have developed a pyrogen test that does not require a laboratory and is not tested on animals. It is expected to be placed on the market soon.https://www.gesundheitsindustrie-bw.de/en/article/news/A-rapid-pyrogen-test-the-human-immune-system-as-model
Bioinspired technologies - 03/04/2020 Diagnostics with molecular scissors – is this also possible for on-site COVID-19 tests? The CRISPR-Cas gene-editing technology is one of the most important developments in molecular biology in recent years. It utilises molecular scissors with which nucleic acids can be cut and edited almost arbitrarily. Researchers in Freiburg, Germany have now successfully used the technology for diagnostic purposes. They are currently working intensively on expanding the system to enable it to detect genome sequences of the novel SARS-CoV-2 virus.https://www.gesundheitsindustrie-bw.de/en/article/news/Diagnostics-with-molecular-scissors-is-this-also-possible-for-on-site-COVID-19-tests
Article - 04/02/2020 Medicine from the blue blood of marine snails A “living pharmacy” crawls on the ocean floor off the coastline that stretches from Southern California to Mexico: biosyn Arzneimittel GmbH, a pharmaceutical company based in the city of Fellbach in southern Germany, produces a drug to treat bladder cancer, using the haemolymph, a vertebrate fluid equivalent to blood, of Megathura crenulata, commonly known as a giant keyhole limpet.https://www.gesundheitsindustrie-bw.de/en/article/news/medicine-from-blue-blood-marine-snails
Article - 30/09/2019 Do gut bacteria have something to do with autism? Autistic people have different gut microorganisms than non-autistic people. Researchers believe that a disturbed intestinal flora may play a role in developmental disorders of the brain such as autism. The emerging new field of metaproteomics could shed light onto the matter. A team led by Prof. Dr. Boris Macek from Tübingen has investigated the bacterial protein pool in the faeces of mice that display autistic behaviour.https://www.gesundheitsindustrie-bw.de/en/article/news/do-gut-bacteria-have-something-to-do-with-autism
Article - 26/07/2019 New test assay leads to discovery of new influenza virus infection route Researchers from the University of Freiburg have recently discovered a completely new mechanism that influenza viruses use to infect cells. This discovery was partly made possible by a so-called emulsion coupling assay - an extremely sensitive, digital detection method developed by Actome GmbH in collaboration with scientists from the Freiburg University of Applied Sciences and Hahn-Schickard. The assay is used to count individual molecules and…https://www.gesundheitsindustrie-bw.de/en/article/news/alternativer-infektionsweg-fuer-grippeviren-durch-neues-testverfahren-entdeckt
Article - 01/07/2019 Microswimmers for guided drug delivery Medicines should act as quickly as possible and ideally only at the site of disease. However, this may be difficult when the medicines are taken up via the digestive tract or the blood system. Researchers at the Max Planck Institute for Intelligent Systems in Stuttgart have now developed a biohybrid microrobot consisting of red blood cells and bacteria that can be loaded with active ingredients.https://www.gesundheitsindustrie-bw.de/en/article/news/microswimmers-guided-drug-delivery
Article - 11/06/2019 New pathogens in beef and cow's milk contributing to the risk of cancer A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
Article - 05/03/2019 Vaccination against oncogenic Epstein-Barr viruses Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.https://www.gesundheitsindustrie-bw.de/en/article/news/vaccination-against-oncogenic-epstein-barr-viruses
Article - 29/01/2019 Targeted RNA editing with the body’s own enzyme activity Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is thus…https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-rna-editing-with-the-bodys-own-enzyme-activity
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Dossier - 14/06/2016 CRISPR/Cas – genome editing is becoming increasingly popular https://www.gesundheitsindustrie-bw.de/en/article/dossier/crisprcas-genome-editing-is-becoming-increasingly-popular
Dossier - 09/02/2015 Chemical tools for biological applications https://www.gesundheitsindustrie-bw.de/en/article/dossier/chemical-tools-for-biological-applications
Dossier - 10/11/2014 Cell and gene therapies from bench to bedside https://www.gesundheitsindustrie-bw.de/en/article/dossier/cell-and-gene-therapies-from-bench-to-bedside
Dossier - 02/06/2014 Bioanalysis techniques for the characterization of biological material Science constantly provides researchers with new challenges biologists and bioanalysts have to deal with and which come from sources as varied as the ever increasing number of resistant pathogenic bacterial strains or the famine conditions in Third-World countries. In the search for scientific truths bioanalysis is the development optimization and application of the entire range of analytical methods available. However we need to keep in mind…https://www.gesundheitsindustrie-bw.de/en/article/dossier/bioanalysis-techniques-for-the-characterization-of-biological-material
Dossier - 31/03/2014 Peptides diverse molecules of life https://www.gesundheitsindustrie-bw.de/en/article/dossier/peptides-diverse-molecules-of-life
Dossier - 20/01/2014 Optogenetics switching cell activity on and off with light What still sounds like science fiction to the general public has long been within reach for many years scientists have been able to manipulate neural activity selectively with light. They use different wavelengths to turn cells on and off as if they were a standard switch. Optogenetics is an emerging technology that combines optics and genetics. The technology is already used in many different ways for many different purposes by numerous research…https://www.gesundheitsindustrie-bw.de/en/article/dossier/optogenetics-switching-cell-activity-on-and-off-with-light
Dossier - 02/12/2013 RNA interference confidence is returning The 15-year history of RNA interference is not short on dramatic effects. It begins with the unexpected discovery and publication of the process of post-transcriptional gene silencing in 1998 for which the two Americans Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or Medicine just eight years after their discovery. In 2001 Thomas Tuschl succeeded in switching off genes in human cells with small synthetic pieces of RNA…https://www.gesundheitsindustrie-bw.de/en/article/dossier/rna-interference-confidence-is-returning
Dossier - 01/07/2013 Electrophysiology from cardiac pacemakers to drug discovery https://www.gesundheitsindustrie-bw.de/en/article/dossier/electrophysiology-from-cardiac-pacemakers-to-drug-discovery
Dossier - 13/05/2013 The human proteome the next major goal https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-human-proteome-the-next-major-goal
Dossier - 15/04/2013 Bioactive plant foods more than just filling The increasing demand for functional foods clearly shows that the role of food is no longer just to meet an essential need. Food that offers additional nutritional benefits is becoming increasingly important for example food that is able to prevent or treat diseases. This kind of food is therefore interesting for consumers the food industry and the healthcare sector alike. Products based on plant raw materials are particularly in demand due to…https://www.gesundheitsindustrie-bw.de/en/article/dossier/bioactive-plant-foods-more-than-just-filling
Dossier - 01/04/2013 Retroviruses from infectious agent to therapeutic assistant Viruses are infectious particles that use the machinery and metabolism of a host cell to replicate. Despite some similarities with accepted forms of life viruses are not considered as such. The family of retroviruses is particularly known for its most notorious representative i. e. the human immunodeficiency virus HIV which leads to AIDS and for which no cure or effective vaccine is currently available. However retroviruses are not only of…https://www.gesundheitsindustrie-bw.de/en/article/dossier/retroviruses-from-infectious-agent-to-therapeutic-assistant
Dossier - 25/03/2013 Biotechnology goes automated Processes that previously required pipetting analysis and production to be carried out manually are increasingly now controlled by automated systems. However this has not necessarily involved a complete reinvention of the wheel instead automation systems used in the plant construction and mechanical engineering sectors are being adapted and optimised for application in the life sciences. https://www.gesundheitsindustrie-bw.de/en/article/dossier/biotechnology-goes-automated
Dossier - 12/03/2012 Regenerative medicine makes use of patients own resources Die Regenerative Medizin bietet neue Therapieoptionen quer durch die ärztlichen Fachgebiete. Zumeist sind es zellbasierte Verfahren und sie werden häufig mit innovativen Biomaterialien kombiniert. Regenerative Therapien vereinen Know-how aus den Biowissenschaften mit moderner Medizintechnik und sie profitieren von den Fortschritten in den Ingenieur- und Materialwissenschaften.https://www.gesundheitsindustrie-bw.de/en/article/dossier/regenerative-medicine-makes-use-of-patients-own-resources